PURPOSE: To describe the frequency, nature, trends, predictors, and outcomes of chemotherapy-related hospitalizations (CRHs) among a nonselected population of cancer patients treated at a community cancer center, and to explore the feasibility of implementing continuous quality improvement methodologies in routine oncology practice. METHODS: We conducted a prospective cohort study of consecutive adult cancer patients who received chemotherapy at a community cancer center January 2003 to December 2006. Demographic, comorbidity, diagnosis, treatment, and laboratory data were collected via medical record abstraction. Hospitalizations were classified as chemotherapy related or unrelated by a multidisciplinary panel. Patients who experienced CRHs were compared with those who did not. Using a randomly sampled subset of cases and controls, we built a logistic regression model to identify independent predictors of CRH. RESULTS: Of 2,068 chemotherapy recipients, 179 (8.7%) experienced 262 CRHs. Most hospitalizations were not chemotherapy related (73.7%). The mean monthly rate of CRH was 1.5%, the median length of stay was 5 days, the most common type of CRH was gastrointestinal (46.1%) followed by infectious (31.4%), and 0.9% of chemotherapy recipients had a fatal CRH. Significant predictors of CRH included having a comorbidity score of 3-4 versus 0 and having a higher creatinine level. CONCLUSIONS: Although the vast majority of chemotherapy recipients did not experience a CRH, these events were, unfortunately, not without serious consequences. Care should be taken when offering chemotherapy to patients with multiple comorbid conditions. Systematic efforts to monitor toxicity can lead directly to improvements in quality of care.
PURPOSE: To describe the frequency, nature, trends, predictors, and outcomes of chemotherapy-related hospitalizations (CRHs) among a nonselected population of cancerpatients treated at a community cancer center, and to explore the feasibility of implementing continuous quality improvement methodologies in routine oncology practice. METHODS: We conducted a prospective cohort study of consecutive adult cancerpatients who received chemotherapy at a community cancer center January 2003 to December 2006. Demographic, comorbidity, diagnosis, treatment, and laboratory data were collected via medical record abstraction. Hospitalizations were classified as chemotherapy related or unrelated by a multidisciplinary panel. Patients who experienced CRHs were compared with those who did not. Using a randomly sampled subset of cases and controls, we built a logistic regression model to identify independent predictors of CRH. RESULTS: Of 2,068 chemotherapy recipients, 179 (8.7%) experienced 262 CRHs. Most hospitalizations were not chemotherapy related (73.7%). The mean monthly rate of CRH was 1.5%, the median length of stay was 5 days, the most common type of CRH was gastrointestinal (46.1%) followed by infectious (31.4%), and 0.9% of chemotherapy recipients had a fatal CRH. Significant predictors of CRH included having a comorbidity score of 3-4 versus 0 and having a higher creatinine level. CONCLUSIONS: Although the vast majority of chemotherapy recipients did not experience a CRH, these events were, unfortunately, not without serious consequences. Care should be taken when offering chemotherapy to patients with multiple comorbid conditions. Systematic efforts to monitor toxicity can lead directly to improvements in quality of care.
Authors: Linda S Elting; Catherine Cooksley; B Nebiyou Bekele; Michael Frumovitz; Elenir B C Avritscher; Charlotte Sun; Diane C Bodurka Journal: Cancer Date: 2006-06-01 Impact factor: 6.860
Authors: Lisa A Ladewski; Steven M Belknap; Jonathan R Nebeker; Oliver Sartor; E Allison Lyons; Timothy C Kuzel; Martin S Tallman; Dennis W Raisch; Amy R Auerbach; Glen T Schumock; Hau C Kwaan; Charles L Bennett Journal: J Clin Oncol Date: 2003-10-15 Impact factor: 44.544
Authors: Michael J Hassett; A James O'Malley; Juliana R Pakes; Joseph P Newhouse; Craig C Earle Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: Michael N Neuss; Christopher E Desch; Kristen K McNiff; Peter D Eisenberg; Dean H Gesme; Joseph O Jacobson; Mohammad Jahanzeb; Jennifer J Padberg; John M Rainey; Jeff J Guo; Joseph V Simone Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Michael S Simon; Wei Du; Lawrence Flaherty; Philip A Philip; Patricia Lorusso; Cheryl Miree; Daryn Smith; Diane R Brown Journal: J Clin Oncol Date: 2004-04-13 Impact factor: 44.544
Authors: G Aprile; F E Pisa; A Follador; L Foltran; F De Pauli; M Mazzer; S Lutrino; C S Sacco; M Mansutti; G Fasola Journal: Support Care Cancer Date: 2012-06-22 Impact factor: 3.603
Authors: Nikki M Carroll; Thomas Delate; Alex Menter; Mark C Hornbrook; Lawrence Kushi; Erin J Aiello Bowles; Elizabeth T Loggers; Debra P Ritzwoller Journal: J Oncol Pract Date: 2015-06-09 Impact factor: 3.840
Authors: Gabriel A Brooks; Ankit J Kansagra; Sowmya R Rao; James I Weitzman; Erica A Linden; Joseph O Jacobson Journal: JAMA Oncol Date: 2015-07 Impact factor: 31.777
Authors: Jordan M Harrison; Philip J Stella; Beth LaVasseur; Paul T Adams; Lauren Swafford; JoAnn Lewis; Kari Mendelsohn-Victor; Christopher R Friese Journal: J Oncol Pract Date: 2016-07-12 Impact factor: 3.840
Authors: Gabriel A Brooks; Thomas A Abrams; Jeffrey A Meyerhardt; Peter C Enzinger; Karen Sommer; Carole K Dalby; Hajime Uno; Joseph O Jacobson; Charles S Fuchs; Deborah Schrag Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544